Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 2Terminated 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Gastroesophageal Reflux 2Barrett Esophagus 2Adenocarcinoma Of Esophagus 1

Interventions

Cyclophosphamide 739Cisplatin 687Gemcitabine 641Bevacizumab 615Carboplatin 604Paclitaxel 600Docetaxel 565Radiotherapy 536Fluorouracil 405Oxaliplatin 387Rituximab 369Doxorubicin 360Capecitabine 342Filgrastim 333Etoposide 328Dexamethasone 312Irinotecan 309pembrolizumab 279Leucovorin 274Cetuximab 267Cytarabine 242Erlotinib Hydrochloride 231Prednisone 227Nivolumab 227Trastuzumab 225Bortezomib 221Vincristine 220Methotrexate 207Pemetrexed 199fludarabine phosphate 195

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Completed × YF 476 × Clear all
NCT01298999 2021-11-23

Trial of a Gastrin Receptor Antagonist in Barrett's Esophagus

Columbia University

Phase 2 Completed
27 enrolled 16 charts
Gastrointestinal

Adenocarcinoma Of Esophagus, Barrett Esophagus, Gastroesophageal Reflux

NCT02597712 2021-04-12

YF476 in Barrett's Esophagus

Trio Medicines Ltd.

Phase 2 Completed
27 enrolled 15 charts
Gastrointestinal

Barrett Esophagus, Gastroesophageal Reflux

Data powered by HemOnc (CC BY 4.0) Colophon âš¡